|
|
Article: Positive results reported from U.S. phase IV trial of frovatriptan.(for menstrually associated migraine headaches)
- Article from:
- Women's Health Weekly
- Article date:
- October 24, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 OCT 24 - (NewsRx.com & NewsRx.net) -- Vernalis Group plc (VER) announced the successful outcome of a large multicenter study that demonstrated the significant benefits of using frovatriptan, its newly marketed antimigraine treatment, in the prophylaxis (prevention) of menstrually associated migraine headaches.
The double-blind, placebo-controlled crossover trial was conducted at 36 clinics in the United States and involved over 500 menstrual migraine sufferers. On average, women in the trial had suffered between 11 and 12 menstrual migraine attacks over the previous 12 months and had a 12-year history of menstrually associated migraine.
Patients ...